Pharma stock hits 10% upper circuit after company migrates from BSE SME to BSE Main Board

Synopsis: Microcap pharma stock Achyut Healthcare Ltd surged 10%  after receiving BSE Main Board migration approval and reflects compliance with eligibility rules like paid-up capital over Rs. 10 cr, promoter holding greater than or equal to 20%, and a 3-year listing history.

This is a pharmaceutical trading company dealing in API, Pharmaceutical products, and medical devices is now in focus after it received approval to migrate to the BSE Mainboard.

With a market capitalisation of Rs. 134 cr, the shares of Achyut Healthcare Ltd are currently trading at Rs. 5.72 per share, hit a 10% upper circuit in today’s market session, making a high of Rs. 5.85, up from its previous close of Rs. 5.32 per share.

Eligibility Criteria to migrate from BSE SME to BSE Mainboard

To migrate from BSE SME to the Main Board, a company must meet financial and business criteria, which are paid-up capital over Rs. 10 cr, average market cap of Rs. 100 cr, promoter holding greater than or equal to 20%, net worth greater than or equal to Rs. 1 cr, and net tangible assets greater than or equal to Rs. 3 cr. The company should have a 3-year listing history, consistent business operations, and at least 1,000 public shareholders.

It must also meet regulatory and liquidity conditions, such as no SEBI debarments, defaults, or pending IBC cases; active trading on greater than or equal to 80% of days in the last 6 months; minimum daily turnover of Rs. 10 lakh; promoter shares fully in demat form; and no unresolved investor complaints. 

Achyut Healthcare Limited has received approval from BSE Limited for the migration of its equity shares from the BSE SME Platform to the BSE Main Board. This development marks an important milestone for the company, reflecting its growth and compliance with the eligibility requirements prescribed for listing on the Main Board platform.

Pursuant to the approval, the equity shares of Achyut Healthcare Limited will be listed and admitted to trading on the BSE Main Board with effect from Friday, January 2, 2026. From this date, the company’s shares will be traded on the Main Board platform instead of the SME platform, enabling wider investor participation and enhanced visibility in the capital markets.

BSE has also issued a notice dated January 1, 2026, to its Trading Members informing them about the said migration. The company has been advised to quote the relevant security code allotted on the Main Board in all future correspondence related to corporate actions such as record dates, dividends, bonus issues, rights issues, preferential issues, or conversion of securities.

The approval and migration signify a key step in the company’s growth journey and reinforce its commitment to transparency, regulatory compliance, and long-term value creation for its stakeholders.

Achyut Healthcare Limited is a pharmaceutical trading company engaged in APIs, pharmaceutical products, and medical devices. The company is committed to delivering high-quality, affordable healthcare solutions while building long-term, family-like relationships with its customers.

It currently reports a ROCE of 2.26% and an ROE of 1.77%. The company is debt-free, indicating a strong and stable capital structure with no financial leverage, which provides flexibility for future growth and investment.

Sales of the company significantly rose from Rs. 0.92 cr in H2FY25 to Rs. 5.64 cr in H1FY26. Operating profit increased from a loss of Rs. 0.12 cr to a profit of Rs. 0.15 cr. Net profit marginally increased to Rs. 0.23 cr from Rs. 0.20 cr.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Pharma stock hits 10% upper circuit after company migrates from BSE SME to BSE Main Board appeared first on Trade Brains.